News

The new company debuted with £96 million in funding to target retinal diseases.

The EACCME accreditation is renewed through 2025.

The trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.

RAFARM and BioNanoSim have entered into an agreement to create the company.

A look at how EDOF technology can be categorised into five types

Debate continues over the best way to apply treatment option

SOE holds a special place in its heart for the up-and-coming young ophthalmologists and is providing them a number of opportunities to hone their skills and establish professional contacts at this meeting.

Novel procedures may hold greater appeal for cataract and refractive surgeons

The European Society of Ophthalmology (SOE) 2023 Congress will convene from June 15 to 17 in Prague, Czech Republic.

Clinical ophthalmology efforts will target the 'busiest' outpatient speciality.

Dr Zeba A. Syed emphasises the importance of performing surgery sooner rather than later for patients with Pseudomonas scleritis

The country is home to 20% of biotechs headquartered in Europe.

Ground-breaking treatment for bullous keratopathy approved in Japan

Therapeutic has fewer adverse effects in patients with POAG and OHT, study results show

Early detection and diagnosis are key for these young patients

Accessibility obstacles could prevent those with sight loss from receiving support and care.

What ophthalmologists want patients to know ahead of UK bank holiday.

Growing evidence supports dual therapy to slow progression.

The countries join 15 other nations that have eliminated the disease.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Physician supervision stood out as the major determining factor behind ‘excellent’ learning outcomes in a clinical environment.

Identifying pre-myopia creates an opportunity to deploy accessible prevention strategies, which could reduce prevalence of myopia in children.

According to Bausch + Lomb and Novaliq, MIEBO is the first prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.

The authors suggest that consumers pay attention to age labeling of toys and consider use of protective goggles, while manufacturers could promote use of safety glasses to protect children’s eyes.

Dr Arun C. Gulani explains how his corneal surface technique offers a contrast to cutting procedures without risk, pain or drama.

Surgeons are performing more minimally invasive glaucoma surgeries and fewer trabeculectomy procedures.